Follow Us
Global Insight. US Access.
Our business model is built around utilizing global experience, alongside in-market expertise, to unlock the best-possible outcomes for our clients.
We use cutting-edge, custom-built Market Access AI solutions to enhance our capabilities, overlaid by the knowledge and experience of our senior Advisors and Consultants. This keeps our costs competitive and our turnaround timely, while ensuring human oversight throughout the review and refinement to deliver meaningful, appropriate, and accurate outputs.
US Services
Our team of global experts can help you build your market access and pricing strategy to maximize your commercial potential. Amid an evolving US policy landscape, IRA drug price negotiation, MFN pricing, dynamic tariffs, and global HTA linkages, costs are increasing and funding is stagnating. Our focus remains on adding value by using new technologies, in a responsible way, to deliver high-quality outputs at pace.
Key US-specific services include:
AI Driven Advantage
Streamlined dossier development
Utilizing our custom, US-specific AI dossier writing technology, Do-BoAMCP. We save clients months of time and money, while ensuring the highest-quality submissions.
Virtual reality (VR) AI closed language model training
Designed for individuals and departments. Dive into realistic simulations, receiving personalized feedback and tailored scenarios to enhance your field team skills, including reimbursement negotiation skills. Our Q-BO is fully private: your data never leave the platform and are never shared with external AI systems.
Meet the US Team
Michael MaleckiUS Launch Strategy Advisor
Michael specialises in US Market Access and Pricing Strategy. His expertise in navigating the complex US payer landscape is well recognized and his analytical acumen is rooted in an in-depth understanding of principal-agent dynamics in healthcare, a focus sharpened during his tenure at Decision Resources Group.
With almost 20 years in US pricing and reimbursement, Michael has held senior roles in Amgen’s Value & Access and Regulatory Policy teams and led Commercial Strategy and Execution at Blue Note Therapeutics. He holds a Ph.D. in Biological Chemistry and Molecular Pharmacology from Harvard Medical School.
Courtney RiceUS Commercialization Advisor
Courtney Rice is a strategy consultant and insights leader with more than 20 years of experience guiding specialty therapies from development through commercialization. Her work focuses on genetic medicine and rare diseases, with a specialization in cell and gene therapy. She played a key role in the global commercial launch of the first systemic gene therapy approved for a rare disease and has since supported the development and global commercialization of 14+ CGT assets.
Courtney’s experience spans payer strategy, brand development, and evidence generation, with a focus on aligning commercial approaches across payers, providers, and health systems. She has worked extensively at the intersection of payer and brand strategy to support coherent commercial decision-making and has deep experience with complex delivery and reimbursement models.
Bridget McMahonUS Market Research Consultant
Bridget has over 15 years of experience in the healthcare and life sciences industry, providing management consulting strategies backed by data-driven insights. She holds a master’s degree in international healthcare management from Imperial College London.
She started her market research career in Europe where she focused on global markets and moved back to her home in the US where she has been working for over a decade on a range of pharmaceutical and biotech assets. With a strong analytics background spanning methodology, research design, and moderation expertise, she has served as a trusted advisor to numerous pharmaceutical product management teams and start-ups.
Our specialized US team is also supported by the global team, including:
Catherine BaconFingerPost CEO
Cath has over 18 years’ experience working in market access. She has an MSc in Neuroscience and her experience has included working with a wide range of different life science companies.
This inspired her to develop market access solutions that address the challenges faced by pharmaceutical companies with small portfolios.
Dr Stefan WalzerSenior Market Access Advisor and AI Tools Inventor
Dr. Stefan Walzer has worked in market access, pricing, health economics and reimbursement since 2004. He is the CEO and founder of MArS Market Access & Pricing Strategy and mAxInsights BV and has inventor of the purpose-built Market Access AI tools we use.
Previously, he spent around nine years as a Global Payer Strategy Lead in big pharma working across different products, franchises and disease areas.
Stefan holds MSc in Economics from the University of Tuebingen, a PhD in Health Economics from the University of Zurich and a Diploma in Clinical Trials from the London School of Hygiene and Tropical Medicine. He has been teaching market access and negotiations since 2012, which includes teaches for the Masters in Consumer Health Care at Charite in Berlin and on market access and health technology assessment at the State University of Baden-Wuerttemberg.
Additionally, he is co-author of more than 40 peer-reviewed scientific articles, more than 500 scientific abstracts and has edited a variety of scientific books.
Meet more of our global team members on the Meet the Team page.
